Latest Thrombolysis Stories
THR-18 significantly decreases the occurrence of intracranial hemorrhage and brain edema, and enhances recovery in acute ischemic stroke patients REHOVOT, Israel, December 18, 2014 /PRNewswire/
KALAMAZOO, Mich., Dec.
Study is most significant stroke treatment clinical trial since NINDS-2 says Society of NeuroInterventional Surgery WASHINGTON, Dec.
KALAMAZOO, Mich., Nov. 6, 2014 /PRNewswire/ -- Stryker Corporation's Trevo® ProVue Retriever has received the Prix Galien USA 2014 Award for Best Medical Technology.
Initial data show that THR-18 significantly decreases the occurrence of intracranial hemorrhage (ICH) and brain edema in acute ischemic stroke (AIS) patients REHOVOT, Israel, November 4, 2014
Many more stroke patients could benefit from thrombolytic treatment (the use of drugs to break up or dissolve blood clots), but it needs to be administered as quickly as possible after the first signs of illness.
At the California Institute for Deep Venous Thrombosis, Dr.
In an analysis that included data from 16 trials performed over the last 45 years, among patients with pulmonary embolism, receipt of therapy to dissolve the blood clot (thrombolysis) was associated with lower rates of death, but increased risks of major bleeding and intracranial hemorrhage.
Bringing clarity to a decades-long debate, a national team of researchers led by experts from the Perelman School of Medicine at the University of Pennsylvania has found that adding clot-busting medications known as thrombolytics to conventional approaches when treating sudden-onset pulmonary embolism patients is associated with 47 percent fewer deaths than using standard intravenous or under-the-skin anticoagulant medications alone.
REHOVOT, Israel, June 2, 2014 /PRNewswire/ -- D-Pharm Ltd.